Nanjing Leads Biolabs Wins EU Orphan Drug Status for LBL-024 in Rare Neuroendocrine Cancer
I'm PortAI, I can summarize articles.
Nanjing Leads Biolabs Co., Ltd. has received Orphan Drug Designation from the European Commission for its bispecific antibody LBL-024 (Opamtistomig) aimed at treating extrapulmonary neuroendocrine carcinoma (EP-NEC). This designation offers regulatory and commercial benefits, including market exclusivity for 10 years upon approval. LBL-024 is the first therapy targeting 4-1BB to reach the registrational stage for EP-NEC and has shown promising results in trials. Analysts rate the stock (HK:9887) as a Buy with a price target of HK$80.27, and the company focuses on innovative oncology therapies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments